Skip to main content


We are an innovative pharmaceutical company determined to improve the lige of people with allergy

We have developed our biotechnology with you in mind. How could we turn on sharp insights on allergy and precision medicine into a better life for you?

ANGANY is a private, French-Canadian pharmaceutical company with mission to change our ability to fight allergy. Our goal is to help people with allergies get their life back.

Leveraging 30 years of research in biotechnology, immunology and vaccinology, and after more than $ 15M of R&D investments, ANGANY has tackled the specific challenges of allergy to invent a new generation of pharmaceuticals. The goal: treatments worthy of precision medicine, simpler, more effective and safer than current desensitization, and based on a more precise diagnosis.

In a world first, ANGANY has developed an exclusive vaccine platform based on synthetic biology. This self-adjuvant vector, ANGANY’s proprietary eBioparticle ™, has demonstrated at the preclinical level the possibility of reversing the allergy dynamics. ANGANY has developed a flexible, fast and easy to scale 3rd generation plant-based production platform.

ANGANY thus wishes to bring lasting solutions into a reality where even today allergy sufferers must too often rely on drugs that only mask the symptoms of allergy. ANGANY has developed a form of immunotherapy that is simple in its administration, and from which we expect safety and long-lasting protective effects. Our goal is to stop the allergy dynamic that affects people and prevent the allergic disease from progressing.

ANGANY anticipates that its vaccine platform will also find direct applications in other therapeutic areas such as cancer, in the treatment of autoimmune, infectious and other diseases, in human and animal health.
ANGANY is a Canadian company founded in 2017 and which continues a mission started in France in 2010 by Dr Loïc Faye and Véronique Gomord and their biotech start-up Angany Genetics SAS.

ANGANY inc. is based in Quebec City; the company owns Angany Innovation SAS, an R&D laboratory located at the Pharmaparc de Val-de-Reuil in Normandy.

Vision, expertise, leadership

Christine Guillen, PharmD, CEO ANGANY

A pharmacist by training, specializing in biotechnology, Ms Guillen’s personal ambition is to develop and make accessible the medicines patients need most. With a solid background in biopharmaceuticals and extensive experience in leading innovative life science companies (ELSALYS BIOTECH, Transgene), she has found in ANGANY the opportunity to apply her skills and experience to the development and marketing of a disruptive technology that can rapidly change the lives of millions of people.  Relying on her structured leadership and proven communication skills, she guides her team, ensures the progress of programs and operations, and speeds up the achievement of the value milestones set out in the company’s development schedule. Her positive, balanced outlook on life makes her a unifying leader.

Angany Innovation SAS: ANGANY’s R&D lab in Val-de-Reuil, France

Angany Innovation SAS is a French company focused on R&D and wholly-owned by ANGANY Inc. Angany Innovation SAS operates state of the art facilities located at the Pharmaparc in Val-de-Reuil in Normandy, France.